Medical/Pharmaceuticals

Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)

HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on...

2026-05-06 08:10 5396

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...

2026-05-06 05:01 3158

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

* PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours * TGA registration provides an approved treatment option in an area of significant unmet me...

2026-05-06 05:01 3496

Hidden Muscle Fat Poses Danger to Heart, Metabolism

OAK BROOK, Ill., May 5, 2026 /PRNewswire/ -- Using a deep learning model to analyze the composition of large muscles on MRI, German researchers found that the proportions of intermuscular fat and lean muscle mass were associated with high blood pressure and unhealthy lipid and blood sugar levels....

2026-05-05 22:00 2600

BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms

Recognition highlights BostonGene's leadership in improving drug development decisions, reducing risk and accelerating patient impact SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan

2026-05-05 22:00 3747

AI Model Analyses Body Composition to Predict Health Risks

OAK BROOK, Ill., May 5, 2026 /PRNewswire/ -- Researchers used AI to analyze whole-body MRI scans from more than 66,000 participants to create the most detailed reference map to date of how fat and muscle are distributed in the human body across age, sex and height. The study was published today i...

2026-05-05 22:00 2757

BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints

SUZHOU, China, May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, B...

2026-05-05 20:20 3423

3Shape appoints new Chief Financial Officer

COPENHAGEN, Denmark, May 5, 2026 /PRNewswire/ -- 3Shape today announced the appointment of Stefan Kratzer as Chief Financial Officer effective 5 May. He will join the Senior Leadership Team and report directly to CEO Jacob Paulsen. The appointment ensures strong leadership continuity, with an exp...

2026-05-05 19:26 2987

Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year

* Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution * Recognition highlights proactive alignment with evolving expectations from global stakeholders INCHEON, South Korea, May 5, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a l...

2026-05-05 19:00 5606

Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination

TAIPEI and SAN DIEGO, May 5, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company today announced the initiation of a global,multi-center clinical trial. The Company has also submitted an Investigational New Drug (IND) application to the U.S. Food...

2026-05-05 15:40 4688

Cleveland Clinic, RIKEN, and IBM Model a 12,635-Atom Protein - the Largest Known to Be Simulated with Quantum Computers

Milestone simulation of biologically meaningful molecules expands quantum-centric supercomputing's role as a scientific tool YORKTOWN HEIGHTS, N.Y. and CLEVELAND, May 5, 2026 /PRNewswire/ -- Scientists at Cleveland Clinic, RIKEN, and IBM (NYSE:IBM ) have used IBM qua...

2026-05-05 12:18 4071

Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)

Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802, a first-in-class, off-the-shelf Treg therapy, in patients with steroid-refractory GVHD HOUSTON, May 5, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, ...

2026-05-05 05:16 3218

New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC

MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology[1], demonstrating that TLX250‑Px (Zircaix®[2], 89 Z...

2026-05-05 05:00 5323

CARiNG Pharmacy Introduces "Empowering Women, Inspiring Wellness" Campaign to Encourage Women to be More Proactive About Their Health

The new campaign focuses on a holistic approach to women's health by connecting inner wellness, outer wellbeing and mental health in everyday life KUALA LUMPUR, Malaysia, May 4, 2026 /PRNewswire/ -- CARiNG Pharmacy, together with Georgetown Pharmacy and Wellings Pharmacy under BIG CARING Group, h...

2026-05-04 16:04 5799

Olympus Signs Global Distribution Agreement with EndoRobotics, Adds Robot-Assisted Technologies to EndoTherapy Portfolio

Partnership Aimed at Expanding Patient Access to Advanced EndoTherapeutic Procedures TOKYO, May 4, 2026 /PRNewswire/ -- Olympus Corporation (Olympus), a global ...

2026-05-04 15:00 4890

TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE

SINGAPORE, May 4, 2026 /PRNewswire/ -- Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were p...

2026-05-04 14:00 4668

XtalPi -Enabled PharmaEngine PEP08 Achieves Enrollment Milestone, with Second Synthetic Lethality Program Underway

SHENZHEN, China, May 4, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has succes...

2026-05-04 08:19 5690

Restore Vision Announces First-in-Human Clinical Interim Results for RV-001, a GPCR-Based Optogenetic Gene Therapy

* Phase I/II clinical trial interim results, out to 168 days, from the two RV-001 dosing cohorts with advanced Retinitis Pigmentosa are presented at key May 2026 meetings: Eyecelerator and Retinal Therapeutics Innovation Summit. * No dose-limiting toxicities (DLTs) or drug-related serious adve...

2026-05-01 14:30 10932

TLX101-Px (Pixlumi®) MAA Accepted in Europe

MELBOURNE, Australia and INDIANAPOLIS, May 1, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the marketing authorization application (MAA) filed in Europe for TLX101-Px (O-(2-[18F]fluoroethyl)-L-tyrosine, 18F-FET), its glioma (brain cancer...

2026-05-01 08:48 8367

Park Systems Launches NX1: The Highest Resolution AFM for Atomic-Scale Imaging in Ambient Conditions

GWACHEON, South Korea, April 30, 2026 /PRNewswire/ -- Park Systems Corp., the world's leading provider of atomic force microscopy (AFM) solutions, today announced the launch of the NX1 — a compact, high-performance AFM that delivers atomic resolution imaging in ambient conditions. Developed in co...

2026-04-30 20:44 4565
1 ... 31323334353637 ... 646